This indicated that the HER2-scFv-engineered macrophage membrane significantly enhanced the targeting of PLGA NPs to HER2+ tumors, resulting in more efficient enrichment of the nanocarrier at the tumor site. The gene discussed is ERBB2; the disease is neoplasm.